Soy lecithin NSAID combo drug protects against cancer with fewer side effects

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSAID), they increased its anticancer properties and reduced its side effects. Findings of the preclinical study of phosphatidylcholine, also called lecithin, appear in the journal Oncology Letters.

"The results support the potential use of NSAIDs associated with phosphatidylcholine for the prevention and treatment of colorectal cancer," said Lenard Lichtenberger, Ph.D., the study's lead investigator and a professor of integrative biology and pharmacology at McGovern Medical School at UTHealth.

The NSAID indomethacin associated with phosphatidylcholine was studied in a head-to-head comparison with three other NSAIDs (one of them aspirin). According to the results, the combination provided superior colorectal cancer protection with less gastrointestinal bleeding. The study was conducted in a mouse model and in laboratory experiments.

Colorectal cancer is the third leading cause of cancer-related death in the United States and is expected to claim 50,630 lives this year.

NSAIDs work by decreasing the production of substances that promote inflammation, pain and fever. They are used to prevent heart disease and reduce arthritis pain. NSAIDs, notably aspirin, also guard against colorectal cancer.

"Many cancers are inflammation based," he said. "The anti-inflammatory drugs also have the potential use for cancer therapy."

However, when taken on a daily basis for months to years, NSAIDs can cause problems, Lichtenberger said. "The intestinal injury is worse than the stomach ulcers, for non-aspirin NSAIDs like indomethacin," he said.

"This is our latest preclinical study on the use of phosphatidylcholine to mitigate the side effects of using NSAIDs and protect against a number of cancers," he said.

Lichtenberger LM, Phan T, Fang D, Dial EJ.
Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro.
Oncl Lett. 2018 May;15(5):6688-6694. doi: 10.3892/ol.2018.8098.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Mushrooms of the Far East hold promise for the ant…

Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities ...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...

Atacand to be divested to Cheplapharm in Europe

AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorot...